12:00-1:00pm          Opportunities to transform drug discovery with world class biotech companies

Rachel Meyers, Ph.D, SVP Research, Alnylam Pharmaceuticals

Dr. Rachel Meyers is Vice President of Research and RNAi Lead Development (RLD) at Alnylam. In this capacity, she plays a key role in the advancement of Alnylam’s RNAi therapeutic programs, from early discovery through clinical development and her team is responsible for program leadership for most of Alnylam’s preclinical and clinical stage programs. Dr. Meyers was honored by Mass High Tech as one of 10 Women to Watch 2007 and by R & D Directions as one of its Top 20 Scientists 2007. Dr. Meyers completed her postdoctoral training at Harvard Medical School in the field of signal transduction, and received her Ph.D. from MIT in the field of in vitro transcription.  She serves as a Scientific Advisor to Editas Medicine.

 

Stéphane Bancel, Chief Executive Officer, Moderna Therapeutics.

Stéphane joined Moderna in the summer of 2011 when it was a one employee and one patent company, after Dr. Noubar Afeyan and the board described to him the technology behind messenger RNA Therapeutics™. He holds a Master of Engineering from École Central Paris, a Master of Science in Chemical Engineering from the University of Minnesota and an MBA from Harvard Business School. Stéphane was elected a 2009 Young Global Leader by the World Economic Forum. He was elected best CEO for investor relations in France in 2009 and was ranked the number one CEO in the biotech sector according to the 2011 Thomson Reuters EXTEL Study. Stéphane serves as a supervisory director of Qiagen N.V., and on the Board of Directors of Syros Pharmaceuticals.

 

Kenneth Rhodes, Ph.D., Chief Scientific Officer, Yumanity Therapeutics.

Dr. Rhodes is chief scientific officer of Yumanity Therapeutics. Prior to Yumanity, Dr. Rhodes served as vice president, neurology discovery at Biogen Idec, where he led a scientific organization focused on discovery and early development of novel protein and small molecule drugs for the treatment of neurodegenerative diseases. During his tenure at Biogen Idec, Dr. Rhodes’ team delivered nine new chemical entities into preclinical development in areas such as multiple sclerosis (MS), Parkinson’s disease and Alzheimer’s disease. Dr. Rhodes earned his Ph.D. in anatomy and neurobiology at Boston University and completed postdoctoral training in systems neuroscience at the National Eye Institute, National Institutes of Health.


1:15-2:15pm       Opportunities in the “big data” revolution in healthcare

Rachel-Meyers_jpg.jpg

Daniel MacArthur, PhD, Co-Director | Medical and Population Genetics, Broad Institute of Harvard and MIT Group Leader | Analytic and Translational Genetics Unit, Massachusetts General Hospital Assistant Professor | Harvard Medical School

Daniel MacArthur is the Co-Director of Medical and Population Genetics at the Broad Institute, and an Assistant Professor at Harvard Medical School and Massachusetts General Hospital. His research focuses on the application of massive-scale genomic data sets to interpret human genetic variation, especially in the context of the diagnosis of rare, severe diseases. He leads the Exome Aggregation Consortium, which has assembled the largest publicly available collection of human genetic variation data at exac.broadinstitute.org, spanning sequencing data from over 60,000 humans. 

 

Enoch Huang, PhD, Executive Director, Computational Sciences of Emphasis, Pfizer

Enoch S. Huang received an AB in Molecular Biology from Princeton University and a PhD in Structural Biology from Stanford University. In 1999, Enoch joined Cereon Genomics as a Computational Biologist. The following year, he accepted a position at Pfizer R&D in Cambridge as a Senior Research Scientist. In 2001, he became department head of the newly formed Molecular Informatics group and joined the site management team. In 2007 he accepted a global role as Head of the Computational Sciences Center of Emphasis. External to Pfizer, Enoch has been an Adjunct Assistant Professor of Bioinformatics at Boston University since 2001. He currently serves on the Editorial Advisory Board for Drug Discovery Today, the Bioinformatics Professional Advisory Committee at Brandeis University, and the Industry Advisory Board of the International Society for Computational Biology.

 

Stephen Cleaver, PhD, Executive Director Informatics Systems, Novartis

Steve received a BS degree in Biology from University of South Florida, Tampa, FL, followed by a Ph.D. in Molecular Pharmacology and Structural Biology from Thomas Jefferson University, Philadelphia, PA. Steve's postdoctoral work, performed at Georgia State University, Atlanta, GA, focused on the determination of the solution structure, by high resolution NMR, of retroviral DNA tandem repeats with particular focus on the dynamics of the CA steps. At Novartis, Steve spent seven years in the Developmental and Molecular Pathways organization focused on applying pathway principles to data mining efforts covering a broad science and technology base. Recently, Steve moved into the IT organization where he leads a global Data Sciences team whose mission is to develop software and big data systems that enable innovative science and scientists at NIBR.


Moderator: Pearl Freier

Pearl Freier is President of Cambridge BioPartners, Inc., a strategic advisory firm specializing in targeted search and business development services for the biopharmaceutical and healthcare technology industries. The firm’s methodologies have been used as best practices for several industry groups throughout North America over the years. Pearl has been quoted in publications including BIO-IT World, The Boston Globe, Nature, The Philadelphia Inquirer and Science and has served the biopharmaceutical and healthcare technology industries for over 10 years.


Keynote speaker: Peter Kolchinsky, PhD

Peter Kolchinsky is a founder and managing director of RA Capital Management, a crossover life fund manager dedicated to evidence-based investing in healthcare and life science companies. He is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools, and serves as a member of the Board of Directors of Dicerna Pharmaceutics and a number of private companies. Peter received a Bachelor’s degree from Cornell University and a PhD in Virology from Harvard University.